Tumor Biology

, Volume 35, Issue 9, pp 8471–8482

From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors

  • Federica Zoratto
  • L. Rossi
  • E. Giordani
  • M. Strudel
  • A. Papa
  • S. Tomao
Review

DOI: 10.1007/s13277-014-2367-1

Cite this article as:
Zoratto, F., Rossi, L., Giordani, E. et al. Tumor Biol. (2014) 35: 8471. doi:10.1007/s13277-014-2367-1

Abstract

In recent years, significant progress has been made in the diagnosis and treatment of gastrointestinal cancers. Researches and clinicians however are still faced with challenges, not the least is the detection and management of tumors with varied gene mutation status. Clarification of the molecular pathology of gastrointestinal cancers may improve treatment options as well as quality of life and the long-term survival of this patient class. Therefore, molecular-targeted therapies have emerged as clinically useful drugs for gastrointestinal cancers cure, and predictive biomarkers have been heralded as the way to develop the right drug for the right patient. Moving from such appealing molecular background, we wrote an overview of the main targeted therapies, with particular interest to monoclonal antibodies that have already been approved in clinical practice or are being tested in gastrointestinal cancers treatment.

Keywords

Gastrointestinal cancersMonoclonal antibodiesMolecular biomarkersPersonalized treatment strategy

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Federica Zoratto
    • 1
  • L. Rossi
    • 2
  • E. Giordani
    • 2
  • M. Strudel
    • 2
  • A. Papa
    • 2
  • S. Tomao
    • 2
  1. 1.Oncology Unit 2Azienda Ospedaliera-Universitaria Pisana, Ospedale Santa ChiaraPisaItaly
  2. 2.Oncology Unit, Department of Medico-Surgical Sciences and Biotechnologies“Sapienza” University of Rome, ICOTLatinaItaly